Recerca i docència
Inici
Omitir vínculos de navegación.     
 
Notícies
Premi FAD
125 Aniversario
Sanitat Respon
Psicotelefon
Psicotelefon
Omitir vínculos de navegación
Informació
corporativa
Usuaris: pacients
i famílies
Benito Menni CASM
Compromís i servei
Recerca
i docència
Professionals
i col·laboradors
Publicacions 

Benito Menni CASM ha publicat nombrosos articles i llibres especialitzats, a més de l’edició periòdica de la revista Informaciones Psiquiátricas que podeu consultar a la web:

http://www.revistahospitalarias.org

                                       
A continuació posem a la vostra disposició la relació de les publicacions recents.

Treballs publicats en revistes internacionals 2010

[1] Amann, B., C. Born, J.M. Crespo, E. Pomarol-Clotet, and P. McKenna Lamotrigine: when and where does it act in affective disorders? A systematic review. Neuroimage Journal of Psychopharmacology (IF: 3.647), 2010.

[2] Bartz, J., D. Simeon, H. Hamilton, S. Kim, S. Crystal, A. Braun, V. Vicens, and E. Hollander Oxytocin can hinder trust and cooperation in borderline personality disorder. Social Cognitive and Affective Neuroscience (IF: 4.203), 2010.

[3] Begum, M. and P.J. McKenna Olfactory reference syndrome: a systematic review of the world literature. Psychological Medicine (IF: 5.012), 2010: p. 1-9.

[4] Bhatt, R., K.R. Laws, and P.J. McKenna False memory in schizophrenia patients with and without delusions. Psychiatry Research (IF: 2.373), 2010. 178(2): p. 260-5.

[5] Delaveau, P., P. Salgado-Pineda, P. Fossati, T. Witjas, J.P. Azulay, and O. Blin Dopaminergic modulation of the default mode network in Parkinson's disease. European Neuropsychopharmacology (IF: 3.684), 2010. 20(11): p. 784-92.

[6] Gomar, J.J., J. Ortiz-Gil, P.J. McKenna, R. Salvador, B. Sans-Sansa, S. Sarro, A. Guerrero, and E. Pomarol-Clotet Validation of the Word Accentuation Test (TAP) as a means of estimating premorbid IQ in Spanish speakers. Schizophrenia Research (IF: 4.458), 2010.

[7] Gomar, J.J., E. Pomarol-Clotet, S. Sarro, R. Salvador, C.E. Myers, and P.J. McKenna Procedural learning in schizophrenia: reconciling the discrepant findings.. Biological Psychiatry (IF: 8.926), 2011. 69(1): p. 49-54.

[8] Iturria-Medina, Y., A.P. Fernandez, D.M. Morris, E.J. Canales-Rodriguez, H.A. Haroon, L.G. Penton, M. Augath, L.G. Garcia, N. Logothetis, G.J. Parker, and L. Melie-Garcia Brain Hemispheric Structural Efficiency and Interconnectivity Rightward Asymmetry in Human and Nonhuman Primates. Cerebral Cortex (IF: 6.979), 2010.

[9] Jauhar, S., A. Blackett, P. Srireddy, and P.J. McKenna Pernicious anaemia presenting as catatonia without signs of anaemia or macrocytosis. British Journal of Psychiatry (IF: 5.777), 2010. 197: p. 244-5.

[10] Lorente-Rovira, E., J.L. Santos-Gomez, M. Moro, J.M. Villagran, and P.J. McKenna Confabulation in schizophrenia: A neuropsychological study. Journal of the International Neuropsychological Society (IF: 2.766), 2010: p. 1-9.

[11] Lynall, M.E., D.S. Bassett, R. Kerwin, P.J. McKenna, M. Kitzbichler, U. Muller, and E. Bullmore Functional Connectivity and Brain Networks in Schizophrenia. Journal of Neuroscience (IF: 7.178), 2010. 30(28): p. 9477-9487.

[12] Mohino, S., A. Pujol, and I. Idiaquez Personality Disorders and Criminal Responsibility in the Spanish Supreme Court. Journal of Forensic Sciences (IF: 1.524), 2011. 56(1): p. 150-154.

[13] Molinuevo, J.L., B. Gomez-Anson, G.C. Monte, B. Bosch, R. Sanchez-Valle, and L. Rami Neuropsychological profile of prodromal Alzheimer's disease (Prd-AD) and their radiological correlates. Archives of Gerontology and Geriatrics (IF: 1.36), 2010.

[14] Musalek, M., V. Larach-Walters, J.P. Lepine, B. Millet, W. Gaebel, and P. (and McKenna) Psychopathology in the 21st century. World Journal of Biological Psychiatry (IF: 5.564), 2010. 11(7): p. 844-51.

[15] Pomarol-Clotet, E., E.J. Canales-Rodriguez, R. Salvador, S. Sarro, J.J. Gomar, F. Vila, J. Ortiz-Gil, Y. Iturria-Medina, A. Capdevila, and P.J. McKenna Medial prefrontal cortex pathology in schizophrenia as revealed by convergent findings from multimodal imaging. Molecular Psychiatry (IF: 15.049), 2010. 15(8): p. 823-30.

[16] Pomarol-Clotet, E., M. Fatjo-Vilas, P.J. McKenna, G.C. Monte, S. Sarro, J. Ortiz-Gil, C. Aguirre, J.J. Gomar, A. Guerrero, R. Landin, A. Capdevila, L. Fananas, and R. Salvador COMT Val158Met polymorphism in relation to activation and de-activation in the prefrontal cortex: A study in patients with schizophrenia and healthy subjects. Neuroimage (IF: 5.739), 2010. 53(3): p. 899-907.

[17] Popovic, D., M. Reinares, B. Amann, M. Salamero, and E. Vieta Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder. Psychopharmacology (IF: 4.103), 2010.

[18] Radua, J., E. Via, M. Catani, and D. Mataix-Cols Voxel-based meta-analysis of regional white-matter volume differences in autism spectrum disorder versus healthy controls. Psychological Medicine (IF: 5.012), 2010: p. 1-12.

[19] Salgado-Pineda, P., E. Fakra, P. Delaveau, P.J. McKenna, E. Pomarol-Clotet, and O. Blin Correlated structural and functional brain abnormalities in the default mode network in schizophrenia patients.. Schizophrenia Research (IF: 4.458), 2010.

[20] Salvador, R., M. Anguera, J.J. Gomar, E.T. Bullmore, and E. Pomarol-Clotet Conditional mutual information maps as descriptors of net connectivity levels in the brain. Front Neuroinformatics, 2010. 4: p. 115.

[21] Salvador, R., S. Sarro, J.J. Gomar, J. Ortiz-Gil, F. Vila, A. Capdevila, E. Bullmore, P.J. McKenna, and E. Pomarol-Clotet Overall brain connectivity maps show cortico-subcortical abnormalities in schizophrenia. Human Brain Mapping (IF: 6.256), 2010. 31(12): p. 2003-14.

[22] Zandi, M.S., S.R. Irani, B. Lang, P. Waters, P.B. Jones, P. McKenna, A.J. Coles, A. Vincent, and B.R. Lennox Disease-relevant autoantibodies in first episode schizophrenia. Journal of Neurology (IF: 2.903), 2010.

[23] Ziauddeen, H., C. Dibben, C. Kipps, J.R. Hodges, and P.J. McKenna Negative schizophrenic symptoms and the frontal lobe syndrome: one and the same?. European Archives of Psychiatry and Clinical Neuroscience (IF: 2.747), 2010.


Treballs publicats en revistes internacionals 2005-2006:

[1] Salvador R, Martinez A, Pomarol-Clotet E, Sarro S, Fletcher P, Bullmore ET. Frequency based mutual information measures between clusters of brain regions in functional magnetic resonance imaging. Neuroimage (2007), doi:101016/jneuroimage200612001. 2007.

[2] Amann BL, Mergl R, Vieta E, Born C, Hermisson I, Seemueller F, et al. A 2-Year, Open-Label Pilot Study of Adjunctive Chromium in Patients With Treatment-Resistant Rapid-Cycling Bipolar Disorder. J Clin Psychopharmacol. 2007 Feb;27(1):104-6.

[3] Sterr A, Padberg F, Amann B, Mergl R, Mulert C, Juckel G, et al. Electroencephalographic abnormalities associated with antidepressant treatment: a comparison of mirtazapine, venlafaxine, citalopram, reboxetine, and amitriptyline. J Clin Psychiatry. 2006 Feb;67(2):325-6.
[4] Sterr A, Amann B, Grunze H. [Prophylaxis of bipolar disorder]. Psychiatr Prax. 2006 Mar;33 Suppl 1:S47-54.

[5] Sarró S, Dueñas RM, Galve L, Mediavilla R, Mensa I, Sole J, et al. Validación de la escala de Calgary en pacientes con esquizofrenia crónica. Informaciones psiquiátricas. 2006;182(4):203-13.

[6] Pomarol-Clotet E, Honey GD, Murray GK, Corlett PR, Absalom AR, Lee M, et al. Psychological effects of ketamine in healthy volunteers. Phenomenological study. Br J Psychiatry. 2006 Aug;189:173-9.

[7] Parthasarathi UD, Harrower T, Tempest M, Hodges JR, Walsh C, McKenna PJ, et al. Psychiatric presentation of voltage-gated potassium channel antibody-associated encephalopathy. Case report. Br J Psychiatry. 2006 Aug;189:182-3.

[8] Menon M, Pomarol-Clotet E, McKenna PJ, McCarthy R. Probabilistic reasoning in schizophrenia: A comparison of the performance of deluded and nondeluded schizophrenic patients and exploration of posible ognitive underpinnings. Cognitive Neuropsychiatry. 2006;11 (6):521-36.

[9] McKenna PJ. What works in schizophrenia: cognitive behaviour therapy is not effective. BMJ. 2006 Aug 12;333(7563):353.

[10] Leeson VC, Laws KR, McKenna PJ. Formal thought disorder is characterised by impaired lexical access. Schizophr Res. 2006 Dec;88(1-3):161-8.

[11] Honey GD, O'Loughlin C, Turner DC, Pomarol-Clotet E, Corlett PR, Fletcher PC. The effects of a subpsychotic dose of ketamine on recognition and source memory for agency: implications for pharmacological modelling of core symptoms of schizophrenia. Neuropsychopharmacology. 2006 Feb;31(2):413-23.

[12] Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med. 2006 Feb 2;354(5):472-82.

[13] Corlett PR, Honey GD, Aitken MR, Dickinson A, Shanks DR, Absalom AR, et al. Frontal responses during learning predict vulnerability to the psychotogenic effects of ketamine: linking cognition, brain activity, and psychosis. Arch Gen Psychiatry. 2006 Jun;63(6):611-21.

[14] Amann B, Sterr A, Vieta E, Stampfer R, Walden J, Grunze H. An exploratory open trial on safety and efficacy of the anticonvulsant retigabine in acute manic patients. J Clin Psychopharmacol. 2006 Oct;26(5):534-6.

[15] Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics. 2005 Apr;15(4):195-200.

[16] San L, Arranz B, Escobar R. Pharmacological management of acutely agitated schizophrenic patients. Curr Pharm Des. 2005;11(19):2471-7.

[17] Ros S, Aguera L, de la Gandara J, Rojo JE, de Pedro JM. Potentiation strategies for treatment-resistant depression. Acta Psychiatr Scand Suppl. 2005(428):14-24, 36.

[18] Rojo JE, Ros S, Aguera L, de la Gandara J, de Pedro JM. Combined antidepressants: clinical experience. Acta Psychiatr Scand Suppl. 2005(428):25-31, 6.

[19] Rojo JE, Gibert K, Cobo J, Rodriguez-Cano E, Vallejo J. Onset of antidepressant action: a pharmacological question? Hum Psychopharmacol. 2005 Aug;20(6):425-33.

[20] Orth M, Amann B, Robertson MM, Rothwell JC. Excitability of motor cortex inhibitory circuits in Tourette syndrome before and after single dose nicotine. Brain. 2005 Jun;128(Pt 6):1292-300.

[21] Orth M, Amann B, Ratnaraj N, Patsalos PN, Rothwell JC. Caffeine has no effect on measures of cortical excitability. Clin Neurophysiol. 2005 Feb;116(2):308-14.

[22] Menon M, Woodward TS, Pomarol-Clotet E, McKenna PJ, McCarthy R. Heightened stimulus salience renders deluded schizophrenics less susceptible to the 'famous names illusion'. Schizophr Res. 2005 Dec 15;80(2-3):369-71.

[23] Leeson VC, Simpson A, McKenna PJ, Laws KR. Executive inhibition and semantic association in schizophrenia. Schizophr Res. 2005 Apr 1;74(1):61-7.

[24] Leeson VC, McKenna PJ, Murray G, Kondel TK, Laws KR. What happens to semantic memory when formal thought disorder remits? Revisiting a case study. Cognit Neuropsychiatry. 2005 Jan;10(1):57-71.

[25] Leeson VC, McKenna PJ, Laws KR. Storage and access procedures in schizophrenia: evidence for a two phase model of lexical impairment. J Clin Exp Neuropsychol. 2005 Aug;27(6):700-10.

[26] Honey GD, Pomarol-Clotet E, Corlett PR, Honey RA, McKenna PJ, Bullmore ET, et al. Functional dysconnectivity in schizophrenia associated with attentional modulation of motor function. Brain. 2005 Nov;128(Pt 11):2597-611.

[27] Honey GD, Honey RA, Sharar SR, Turner DC, Pomarol-Clotet E, Kumaran D, et al. Impairment of specific episodic memory processes by sub-psychotic doses of ketamine: the effects of levels of processing at encoding and of the subsequent retrieval task. Psychopharmacology (Berl). 2005 Sep;181(3):445-57.

[28] Gajwani P, Forsthoff A, Muzina D, Amann B, Gao K, Elhaj O, et al. Antiepileptic drugs in mood-disordered patients. Epilepsia. 2005;46 Suppl 4:38-44.

[29] Dibben CR, Kalavalapalli SS, Linnington HE, Hynes FA, Dinneen SF, Adler AI, et al. Diabetes associated with atypical antipsychotic treatment may be severe but reversible: case report. Int J Psychiatry Med. 2005;35(3):307-11.

[30] de la Gandara J, Rojo JE, Ros S, Aguera L, de Pedro JM. Neuropharmacological basis of combining antidepressants. Acta Psychiatr Scand Suppl. 2005(428):11-3, 36.

[31] de la Gandara J, Aguera L, Rojo JE, Ros S, de Pedro JM. Use of antidepressant combinations: which, when and why? Results of a Spanish survey. Acta Psychiatr Scand Suppl. 2005(428):32-6.

[32] de la Gandara J, Aguera L, Rojo JE, Ros S. Working group on combined antidepressants (G.E.A.A.: grupo para el estudio de las asociaciones de antidepresivos). Acta Psychiatr Scand Suppl. 2005(428):5-6.

[33] Barrera A, McKenna PJ, Berrios GE. Formal thought disorder in schizophrenia: an executive or a semantic deficit? Psychol Med. 2005 Jan;35(1):121-32.

[34] Amann B, Sterr A, Mergl R, Dittmann S, Seemuller F, Dobmeier M, et al. Zotepine loading in acute and severely manic patients: a pilot study. Bipolar Disord. 2005 Oct;7(5):471-6.

[35] Amann B, Grunze H. Neurochemical underpinnings in bipolar disorder and epilepsy. Epilepsia. 2005;46 Suppl 4:26-30.

[36] Aguera LF, Rojo JE, Ros S, de la Gandara J, de Pedro JM. Antidepressant combinations: epidemiological considerations. Acta Psychiatr Scand Suppl. 2005(428):7-10, 36.

Llibres

[1] McKenna PJ. Schizophrenia and related syndromes. 2nd ed. Hove ; New York: Taylor & Francis 2007.

[2] McKenna PJ, Oh TM. Schizophrenic speech : making sense of bathroots and ponds that fall in doorways.
     Cambridge ; New York: Cambridge University Press 2005.

[3] McKenna PJ. Schizophrenia and related syndromes. Oxford ; New York: Oxford University Press 1994. 

Mapa Web/Contacta/Privacitat Benito Menni , Complex Assistencial en Salut Mental
  C/ Dr.Antoni Pujadas, 38 ,08830 Sant Boi de Llobregat (Barcelona)Tel: 93- 652 99 99 Fax: 93- 640 02 68
hospital@hospitalbenitomenni.org